Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27618356.
- Also identified by DOI 10.3949/ccjm.83a.15092.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.
Medical subject headings
- Acute Coronary Syndrome
- Platelet Aggregation Inhibitors